|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E (APOE) E4, apolipoprotein B-100 (APOB) Q3611 allele, the angiotensin converting enzyme (ACE) deletion (D) allele and glycoprotein IIIa (GP3A) P33 mutant allele are reported to predispose to early-onset coronary heart disease (CHD).
|
10463820 |
1999 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, a cross-sectional analysis was performed to evaluate the potential relationship between the ACE I/D genotypes and the LV mass index in 289 non-insulin-dependent diabetes mellitus (NIDDM) subjects without known coronary artery disease.
|
10371375 |
1999 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The beneficial effect of angiotensin-converting enzyme inhibition has been shown to be consistent across subgroups in stable coronary artery disease.
|
18520711 |
2008 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, our study suggests that genetic polymorphisms of angiotensin-converting enzyme insertion/deletion are associated with in-stent restenosis in coronary artery disease patients following coronary stenting.
|
28196432 |
2017 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In association analysis the ACE genotype frequencies of probands with CHD did not differ from those of healthy controls.
|
11427204 |
2001 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have tested the hypothesis that the angiotensin-converting enzyme (ACE) DD genotype and the angiotensin II type I receptor (AT1R) gene C allele represent the common link between microalbuminuria and coronary heart disease.
|
9351388 |
1997 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A multiple logistic regression analysis introducing the typical risk factors for CHD (age, gender, smoking, BMI > 26 kg/m 2, LDL elevation, HbA1c > 7 %) could not identify the ACE gene I/D-polymorphism as an independent risk factor for CHD (p = 0.87).
|
12669270 |
2003 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR study).
|
27283338 |
2017 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
|
31370961 |
2019 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of deletion (D) allele in angiotensin converting enzyme (ACE) gene polymorphism is associated with coronary artery disease.
|
17285438 |
2007 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present results show that subjects with the ACE/DD genotype are not at increased risk for CHD because of insulin resistance, relative hyperglycemia and hyperinsulinemia, or a dyslipidemia characterized by a high triglyceride and low HDL cholesterol concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
|
7773733 |
1995 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of angiotensin-converting enzyme polymorphism with coronary artery disease in Iranian patients with unipolar depression.
|
22683751 |
2012 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified indications for medication (statins, aspirin, ACE inhibitors, clopidogrel) recommended in UK National Institute for Clinical Excellence (NICE) guidance for CHD (high risk, stable angina, stable angina plus diabetes, unstable angina, and myocardial infarction) and measured the persistence of indicated medication (time from initiation to discontinuation) across quintiles of the Welsh Index of Multiple Deprivation, an area-based measure of socio-economic inequality, using Cox regression frailty models.
|
29522561 |
2018 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It has been suggested that the insertion (I)/deletion (D) polymorphism of the angiotensin-converting enzyme (ACE) gene is an independent risk factor for coronary artery disease, but its relation to stroke has not yet been proven.
|
8784123 |
1996 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interactions between ACE and angiotensin II type-1 receptors may have clinical implications for preventing and managing CHD.
|
8869131 |
1995 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine whether the angiotensin-converting enzyme (ACE) insertion-deletion (ID) polymorphism interacts with pravastatin to modify the risk of coronary heart disease (CHD) and other cardiovascular end points in a large clinical trial.
|
17174637 |
2007 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease.
|
20655894 |
2010 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease.
|
28710178 |
2017 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Considering the possible interaction between this polymorphism and smoking, we evaluated the association between ACE I/D polymorphism and myocardial infarction (MI), mortality due to coronary heart disease (CHD), and cardiovascular disease (CVD).
|
15635071 |
2005 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prior stroke/TIA and/or PAD patients were less likely to receive evidence-based medical therapies (dual antiplatelet therapy: stroke/TIA= 88.6%, PAD= 86.6%, stroke/TIA+PAD= 85.7%, none= 92.2%, p<0.001; β-blockers: stroke/TIA= 77.1%, PAD= 72.1%, stroke/TIA+PAD= 71.9%, none= 80.8%, p<0.001; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: stroke/TIA= 86.3%, PAD= 83.6%, stroke/TIA+PAD= 83.2%, none= 87.1%, p=0.030) and to undergo percutaneous revascularization (stroke/TIA= 52.8%, PAD= 45.6%, stroke/TIA+PAD= 43.7%, none= 67.9%, p<0.001), despite more extensive coronary artery disease (three-vessel disease: stroke/TIA= 29.1%, PAD= 38.3%, stroke/TIA+PAD= 38.3%, none= 20.2%, p<0.001).
|
28627932 |
2018 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Effect of ACE I/D Polymorphisms Alone and With Concomitant Risk Factors on Coronary Artery Disease.
|
27895197 |
2018 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By contrast, there was no evidence of a significant increase in the risk of CHD or myocardial infarction among individuals with ACE DD.
|
7783537 |
1995 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several small, short-term trials suggested benefit on albuminuria in subjects with diabetes; however, results were not definitive.Welty et al. showed that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 1 year slowed progression of early-stage albuminuria in subjects with diabetes with clinical coronary artery disease on an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, the majority of whom had an albumin/creatinine ratio (ACR) < 30 μg/mg.
|
30684085 |
2019 |
|
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ACE insertion/deletion gene polymorphism is associated neither with the prevalence nor the extent of coronary artery disease, nor with myocardial infarction in this relatively large sample of Caucasian men and women.
|
10462466 |
1999 |
|
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targets of angiotensin converting enzyme (ACE) inhibitors might include not only ACE but also MMP-9, and ACE seems to be closely associated with complications of hypertension such as cardiovascular remodeling whereas MMP-9 is closely related to coronary diseases.
|
19355890 |
2009 |